MyMedR

Displaying all 4 publications

Abstract:

Sort:

Measuring Vertical Jump Height With Artificial Intelligence Through a Cell Phone: A Validity and Reliability Report

Tan ECH, Weng Onn S, Montalvo S

J Strength Cond Res, 2024 Sep 01;38(9):e529-e533.
PMID: 38953840 DOI: 10.1519/JSC.0000000000004854

Erik, HT, Onn, SW, and Montalvo, S. Vertical jump height with artificial intelligence through a cell phone: a validity and reliability report. J Strength Cond Res 38(9): e529-e533, 2024-This study estimated the reliability and validity of an artificial intelligence (AI)-driven model in the My Jump 2 (My Jump Lab ) for estimating vertical jump height compared with the Force Platform (FP). The cross-sectional study involved 88 athletes (33 female and 55 male athletes), performing a total of 264 countermovement jumps with hands on hips. "Jump heights were simultaneously measured using the FP and the My Jump 2 app." The FP estimated jump heights using the impulse-momentum method, whereas My Jump 2 used the flight-time method, with the latter using an AI feature for automated detection of jump take-off and landing. Results indicated high reliability for the AI model (intraclass correlation coefficient [ICC 1,3 ] = 0.980, coefficient of variation [CV] = 4.12) and FP (ICC 1,3 = 0.990, CV = 2.92). Validity assessment showed strong agreement between the AI model and FP (ICC 2,k = 0.973). This was also supported by the Bland-Altman analysis, and the ordinary least products regression revealed no significant systematic or proportional bias. The AI-driven model in My Jump 2 is highly reliable and valid for estimating jump height. Strength and conditioning professionals may use the AI-based mobile app for accurate jump height measurements, offering a practical and efficient alternative to traditional methods.
Fulltext An understanding of the psychological challenges faced by student athletes and how they manage

Shamir Das K.N. Kavidas, Alexius, Cheang, Weng, Onn

Malaysian Journal of Qualitative Research, 2019;5(2):22-30.
MyJurnal

Student athletes represent a unique segment of society, having to manage a set of expectations and challenges that are distinct and psychologically demanding. They are expected to achieve the highest level of sporting excellence while also performing well academically. A basic qualitative study was used to gain an understanding of the nature and type of psychological challenges faced, and ways the student athletes successfully managed or was currently managing those challenges. The results entailed two overlapping groups of challenges; internal and external, where internal consisted of emotional strain, expectations from one’s self, balance between sports and studies, and present feelings of regret, while external consisted of issues with their coach, perception of others, and transition to tertiary education. Additionally, there were three ways of managing those challenges namely through problem-focused coping, emotion-focused coping, and experiential learning. Those three domains are further explored and discussed, with consideration to the local context and the role of individual differences.
Fulltext The role of intravitreal anti-vascular endothelial growth factor injection in peripheral exudative hemorrhagic chorioretinopathy: A systematic review

Gowda A, Bahrami B, Jie WWJ, Casson R, Chan WO

Surv Ophthalmol, 2024;69(2):173-178.
PMID: 37806565 DOI: 10.1016/j.survophthal.2023.10.004

Anti-vascular endothelial growth factor (anti-VEGF) injections have revolutionized the field of ophthalmology, and their use in a variety of retinal diseases is growing. One target disease is peripheral exudative hemorrhagic chorioretinopathy, a disease that is uncommon and poorly understood. Despite this, there are numerous studies and case reports outlining the potential role of intravitreal injection of anti-VEGF medicines to treat it. As such, an evidence-based understanding of its risk-benefit profile is vital. We performed a comprehensive search in the PubMed, Google Scholar, and Cochrane databases for published studies and case reports relating to the use of anti-VEGF injections in peripheral exudative hemorrhagic chorioretinopathy. Anti-VEGF was first used in 2010 to aid in the management of peripheral exudative hemorrhagic chorioretinopathy. Since then, it has been increasingly used to manage this disease. Other potential management strategies, including laser photocoagulation, cryotherapy, photodynamic therapy, and vitrectomy are explored and compared with anti-VEGF where possible. Anti-VEGF appears to be an effective therapy in managing peripheral exudative hemorrhagic chorioretinopathy, especially when there is an exudative threat to the macula.
Topical dorzolamide for macular holes: A randomised, double-blind, placebo-controlled trial

Lee YM, Bahrami B, Baranage D, Sivagurunathan PD, Wong W, Bausili MM, et al.

Clin Exp Ophthalmol, 2024 Aug 15.
PMID: 39145570 DOI: 10.1111/ceo.14432

BACKGROUND: To assess topical dorzolamide as medical therapy for idiopathic full-thickness macular holes (FTMHs).
METHODS: Randomised, double-blinded, placebo-controlled, single-centre clinical trial involving 32 patients with idiopathic small FTMHs (<400 μm $$ \upmu \mathrm{m} $$ ). Participants in both arms used topical dorzolamide 2% or saline thrice daily for 8 weeks with monthly OCT. Those with persisting FTMH underwent vitrectomy with ILM peel and gas tamponade. The primary outcome was the rate of FTMH closure at the end of treatment.
RESULTS: Between 6 March 2020 and 16 June 2023, 32 eligible patients were enrolled: 16 participants in each arm. All participants in both groups were included in the final analysis. At the final visit, 3 of 16 (18.8%) patients in both the topical dorzolamide and placebo group demonstrated closure. There was no statistically significant difference in the proportion of FTMH closure between the control and treatment group (p = 1.00), nor statistically significant difference in the mean change in best corrected visual acuity (BCVA; p = 0.909). There was no difference in the change in FTMH diameter between groups (p = 0.225). No serious adverse events were reported in either group.
CONCLUSION: Topical dorzolamide was safe but not superior to placebo in the functional and anatomical outcomes of FTMH.